Gezelius, E.; Bendahl, P.-O.; Gallo, W.; de Oliveira, K.G.; Ek, L.; Bergman, B.; Sundberg, J.; Melander, O.; Belting, M.
Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN). Cancers 2022, 14, 1307.
https://doi.org/10.3390/cancers14051307
AMA Style
Gezelius E, Bendahl P-O, Gallo W, de Oliveira KG, Ek L, Bergman B, Sundberg J, Melander O, Belting M.
Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN). Cancers. 2022; 14(5):1307.
https://doi.org/10.3390/cancers14051307
Chicago/Turabian Style
Gezelius, Emelie, Pär-Ola Bendahl, Widet Gallo, Kelin Gonçalves de Oliveira, Lars Ek, Bengt Bergman, Jan Sundberg, Olle Melander, and Mattias Belting.
2022. "Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)" Cancers 14, no. 5: 1307.
https://doi.org/10.3390/cancers14051307
APA Style
Gezelius, E., Bendahl, P.-O., Gallo, W., de Oliveira, K. G., Ek, L., Bergman, B., Sundberg, J., Melander, O., & Belting, M.
(2022). Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN). Cancers, 14(5), 1307.
https://doi.org/10.3390/cancers14051307
